Secandary efficacy variables included proportion of responders (i.e., patients with a ‡50% reduction in standardized seizure frequency); relative reduction in standardized seizure frequency; number of days with seizures; proportion of seizure-free patients (100% seizure reduction); and proportion of patients with a ‡ 25% exacerbation in standardized seizure frequency compared to baseline.